HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J cuts jobs and invests in core brands

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson will eliminate 6% to 7% of its global workforce in response to external pressures on the health care industry, the company announced Nov. 3. Cuts will come across all three of the company's core businesses: consumer products, pharmaceuticals and medical devices. Eliminations will take place globally, but mostly outside the U.S., and will reduce "layers of management," CEO William Weldon said during a same-day conference call. The plan will yield pre-tax cost savings of $1.4 bil. to $1.7 bil. in 2011, with $800 mil. to $900 mil. expected to be achieved in 2010. J&J plans to invest the savings in key innovation opportunities and core businesses, including "iconic brands," such as mouthwash Listerine and skin care lines Aveeno and Neutrogena, Weldon said

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel